Skip to main navigation
Skip to search
Skip to main content
University of Illinois Urbana-Champaign Home
LOGIN & Help
Home
Profiles
Research units
Research & Scholarship
Datasets
Honors
Press/Media
Activities
Search by expertise, name or affiliation
Biomaterial-Based In Situ Cancer Vaccines
Yang Bo,
Hua Wang
Materials Science and Engineering
Bioengineering
Materials Research Lab
Biomedical and Translational Sciences
Beckman Institute for Advanced Science and Technology
Carl R. Woese Institute for Genomic Biology
Research output
:
Contribution to journal
›
Review article
›
peer-review
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Biomaterial-Based In Situ Cancer Vaccines'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Biomaterials
100%
In Situ Vaccine
100%
Tumor Antigen
40%
Cancer Immunotherapy
40%
Tumor
20%
In Situ
20%
Therapeutic Efficacy
20%
Antigen-presenting Cells
20%
Cancer Treatment
20%
Cellular Response
20%
Solid Tumors
20%
Design Criteria
20%
Immune Cells
20%
Safety Profile
20%
Peptide Synthesis
20%
T Cell Priming
20%
Synergize
20%
FDA-approved Drugs
20%
Antigen-specific
20%
Troubleshooting
20%
RNA Extraction
20%
Peptide Antigen
20%
Therapeutic Vaccine
20%
Humoral Response
20%
Cytotoxic T Cell Response
20%
Mutation Analysis
20%
Artificial Materials
20%
Living Materials
20%
Cancer Vaccine
20%
Antigen Screening
20%
Epitope Prediction
20%
Tumor Cell Isolation
20%
Medicine and Dentistry
Biocompatible Material
100%
Cancer Vaccine
100%
Tumor Antigen
28%
Cancer Immunotherapy
28%
Neoplasm
14%
Tumor Cell
14%
T Cell
14%
Antigen Presenting Cell
14%
Combination Therapy
14%
Cancer Therapy
14%
Solid Malignant Neoplasm
14%
Antigen
14%
Antigen Specificity
14%
Immunocompetent Cell
14%
Epitope
14%
Cytotoxic T-Cell
14%
DNA RNA Hybridization
14%
Adjuvant
14%
Peptide Synthesis
14%
Pharmacology, Toxicology and Pharmaceutical Science
Biomaterial
100%
Cancer Vaccine
100%
Malignant Neoplasm
42%
Neoplasm
28%
Immunotherapy
28%
Tumor Antigen
28%
Combination Therapy
14%
Solid Malignant Neoplasm
14%
Epitope
14%
Adjuvant
14%
Antigen
14%
Immunology and Microbiology
Cancer Vaccine
100%
Tumor Antigen
28%
Cancer Immunotherapy
28%
T Cell
14%
Epitope
14%
Antigen
14%
Tumor Cell
14%
Immunocompetent Cell
14%
Antigen-Presenting Cell
14%
Antigen Specificity
14%
Adjuvant
14%
DNA RNA Hybridization
14%
Cytotoxic T Cell
14%
Cell Isolation
14%
Peptide Synthesis
14%
RNA Extraction
14%
Material Science
Tumor
100%
Biomaterial
100%
T-Cells
40%
Epitope
20%